ArticleScientific reports2025
Serum fibrinogen is not elevated in patients with myasthenia gravis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Proteomic and machine learning analysis predicts treatment response signatures in Myasthenia Gravis.Journal of translational medicine · 2026Trial
- On the road to blood biomarkers in myasthenia gravis (MG): Beyond clinical scales.Journal of neuromuscular diseases · 2026Review
- Proteomic and Machine Learning Analysis Predicts Treatment Response Signatures in Myasthenia Gravis.Research square · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Myasthenia gravis (MG) is an autoimmune, autoantibody-mediated disease characterized by fatigable weakness of skeletal muscles. MG is a heterogeneous disease that currently lacks a robust biomarker for diagnosing all subtypes. Residual serum fibrinogen was found to be elevated 1000-fold in patients with MG in one study and posited to represent a universal diagnostic biomarker for MG. We set out to confirm elevated serum fibrinogen in patients with all subtypes of MG. We employed multiple methodologies to compare fibrinogen levels between MG patients and controls, using samples from independent cohorts. With enzyme-linked immunosorbent assay (ELISA), fibrinogen levels in sera from MG patients were not significantly different from controls. And in plasma samples, MG patients had a significantly lower amount of fibrinogen compared to controls. Using liquid chromatography-mass spectrometry (LC-MS), the abundance of serum fibrinogen-α was not elevated in patients compared to controls, and patients had a significantly lower abundance of serum fibrinogen-ß and fibrinogen-γ compared to controls. Our results do not support serum fibrinogen to be a diagnostic biomarker for MG and underscore the need for replication of novel findings to ensure our common goal of identifying effective biomarkers for MG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.